Back to Search
Start Over
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
- Source :
- Postgraduate Medicine; Nov2017, Vol. 129 Issue 8, p822-827, 6p
- Publication Year :
- 2017
-
Abstract
- Residual cardiovascular (CV) risk persists even in statin-treated patients with optimized low-density lipoprotein cholesterol (LDL-C) levels. Other pathways beyond cholesterol contribute to CV risk and the key to reducing residual risk may be addressing non-cholesterol risk factors through pleiotropic mechanisms. The purpose of this review is to examine the literature relating to the potential role of the omega-3 fatty acid eicosapentaenoic acid (EPA) in reducing residual CV risk. The literature shows that EPA can robustly lower plasma triglyceride (TG) levels without raising LDL-C levels and documents EPA to have a broad range of beneficial effects on the atherosclerotic pathway, including those on lipids, lipoproteins, inflammation, oxidation, phospholipid membranes, and the atherosclerotic plaque itself. Clinical imaging studies have consistently demonstrated that EPA decreases plaque vulnerability and prevents plaque progression. The evidence therefore points to a potential role for EPA to reduce residual CV risk. A large randomized study of statin-treated Japanese patients demonstrated that EPA ethyl ester reduced major coronary events by 19% (P = 0.011). However, while there has been significant benefit demonstrated in this and another Japanese CV outcomes study, the question as to whether EPA can play a role in reducing residual CV risk remains to be addressed in broader populations. The large, global, ongoing, randomized, placebo-controlled REDUCE-IT study of high-risk statin-treated patients with persistent hypertriglyceridemia is currently underway to investigate the potential of icosapent ethyl (high-purity prescription EPA ethyl ester) as an add-on therapy to reduce residual CV risk. [ABSTRACT FROM AUTHOR]
- Subjects :
- CARDIOVASCULAR disease prevention
EICOSAPENTAENOIC acid
HYPERTRIGLYCERIDEMIA treatment
STATINS (Cardiovascular agents)
INFLAMMATION
LIPOPROTEINS
LOW density lipoproteins
THERAPEUTICS
ATHEROSCLEROSIS prevention
DRUG therapy for hyperlipidemia
ATHEROSCLEROSIS
CARDIOVASCULAR diseases
HYPERLIPIDEMIA
TRIGLYCERIDES
DISEASE complications
Subjects
Details
- Language :
- English
- ISSN :
- 00325481
- Volume :
- 129
- Issue :
- 8
- Database :
- Supplemental Index
- Journal :
- Postgraduate Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 126206773
- Full Text :
- https://doi.org/10.1080/00325481.2017.1385365